Floatz logo

Nepenthe

Cancer-Related Condition

Instituto Nacional de Cancer, BrazilSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Cancer-Related Condition cohort.

Asset / SponsorPhaseRating
Oxycodone
Deventer Ziekenhuis
Phase 4BB
Lidocaine
National and Kapodistrian University of Athens
Phase 2/3BB
Ethylicum
Sindh Institute of Urology and Transplantation
Phase 4BB
Tanezumab
Pfizer
Phase 3BB
Mirtazapine
Montefiore Medical Center
Phase 4BB

View all 20 →

Same molecule, other indications

Nepenthe is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative · Phase 4
75 / 100
View asset →
chronic pain syndromeActive
BBB
Indicative · Phase 4
74 / 100
View asset →
post-operative pain, non-human animalActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →